Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7351993 | 0.82 | — | — | |
| SCHEMBL12744436 | 0.79 | KDM1A (0.43) | HRH3 | |
| SCHEMBL12015832 | 0.78 | CARM1 (0.41) | HRH3KMT2A | |
| SCHEMBL12015831 | 0.76 | PAOX (0.39) | SMO | |
| SCHEMBL1219941 | 0.76 | HRH3 (0.44) | HRH3KMT2A | |
| SCHEMBL16190266 | 0.74 | POLB (0.35) | SMOKMT2A | |
| SCHEMBL7910011 | 0.74 | DRD2 (0.45) | SMOKMT2AMEN1 | |
| SCHEMBL1180845 | 0.73 | POLB (0.46) | KMT2AMEN1 | |
| SCHEMBL8114400 | 0.73 | POLB (0.46) | KMT2AMEN1 | |
| SCHEMBL24911710 | 0.72 | ALOX15 (0.39) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110574-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | IPSEN S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | IPSEN S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7858789-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090149652-A1 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES | 2009-06-11 | — | — | US | disclosed |
| US-7393861-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-07-01 | — | — | US | disclosed |
| US-7393861-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149652-A1 | Derivatives of 4-aminopiperidine and their use as a medicament | SSTR4, SSTR3, SSTR1 | SMO 2184/4885HRH3 114/4885KMT2A 2523/4885 |
| US-20110059971-A1 | DERIVATIVES OF 4-AMINOPIPERIDINE AND THEIR USE AS A MEDICAMENT | SSTR4, SSTR3, SSTR1 | SMO 2184/4885HRH3 114/4885KMT2A 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.